Results 271 to 280 of about 1,461,609 (326)

Application of Immune Checkpoint Inhibitors in Cancer

MedComm, Volume 6, Issue 8, August 2025.
Immune checkpoint inhibitors (ICIs) revolutionize oncology by harnessing immunity against advanced cancers. This review systematically explores ICI mechanisms, clinical applications in advanced malignancies (e.g., head and neck squamous cell carcinoma, esophageal cancer, non‐small cell lung cancer, breast cancer, hepatocellular carcinoma, and bladder ...
Zhijun Chen, Zihan Song, Shichen Den, Wei Zhang, Mengjia Han, Tianhang Lan, Xiaokang Du, Jingyun Ning, XinHui Chen, Haoming Lin, Rui Zhang   +10 more
wiley   +1 more source

Comparison of enriched charge variants from different anti-CD3 bispecific antibodies reveals differential susceptibility of each bispecific arm to post-translational modification. [PDF]

Protein Sci
Nguyen JB, Liu S, Howie DA, Oberholtzer ZR, Ong ET, Rao R, Prinston JE, Dikiy I, Wu J, Wu Z, Zhao Y, Li M, Molden R, Molina G, Provoncha K, Sandu C, Qiu H, Li N, Matousek W, Rosconi MP, Pyles EA.   +20 more
europepmc   +1 more source

Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR‐SCREEN‐2 Study

Cancer Science, Volume 116, Issue 8, Page 2218-2231, August 2025.
ABSTRACT Claudin 18.2 (CLDN18.2), a tight junction protein isoform, is an emerging therapeutic target in oncology. CLDN18 is well‐characterized in gastric cancer, but its pan‐cancer expression profiles and isoform distributions are poorly documented.
Tadayoshi Hashimoto, Naoko Iida, Yoshiaki Nakamura, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, Susumu Okano, Wataru Yamagami, Naoya Yamazaki, Shigenori Kadowaki, Makoto Ueno, Shogen Boku, Eiji Oki, Yoshito Komatsu, Satoshi Yuki, Akitaka Makiyama, Takatsugu Ogata, Naoki Takahashi, Naohiro Okano, Tomohiro Nishina, Naoya Sakamoto, Takeshi Kuwata, Riu Yamashita, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Kohei Shitara, Takayuki Yoshino   +28 more
wiley   +1 more source

Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening. [PDF]

MAbs
Metcalf KJ, Wo G, Zaragoza JP, Raoufi F, Baker J, Chen D, Derebe M, Hogan J, Hsu A, Kofman E, Leigh D, Li M, Malashock D, Mann C, Motlagh S, Park J, Sathiyamoorthy K, Shidhore M, Tang Y, Teng K, Williams K, Waight A, Yilmaz S, Zhang F, Zhong H, Fayadat-Dilman L, Bailly M.   +26 more
europepmc   +1 more source

Hijacking erythropoietin: A tumour‐intrinsic strategy to escape immune surveillance

Clinical and Translational Medicine, Volume 15, Issue 8, August 2025.
David Kung‐Chun Chiu, Edgar G Engleman
wiley   +1 more source

Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro. [PDF]

PLoS One
Kitidee K, Amonyingcharoen S, Preedagasamzin S, Atjanasuppat K, Sawaisorn P, Srimorkun P, Petvises S, Chaicumpa W, Borwornpinyo S, Anurathapan U, Hongeng S.   +10 more
europepmc   +1 more source

Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions. [PDF]

Int J Mol Sci
Damiani D, Tiribelli M.
europepmc   +1 more source

Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. [PDF]

J Hematol Oncol
Bock AM, Epperla N.
europepmc   +1 more source